Silverarc Capital Management’s Climb Bio CLYM Stock Holding History

Silverarc Capital Management’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-684,908	Closed	-$4.69M	–	95
2026 Q1	$4.69M	Buy	+684,908	New	+$3.95M	0.48%	45
2023 Q4	–	Sell	-121,110	Closed	-$319K	–	90
2023 Q3	$319K	Sell	121,110 -372,979	-75%	-$1.02M	0.1%	71
2023 Q2	$1.38M	Buy	494,089 +8,134	+2%	+$24.7K	0.43%	51
2023 Q1	$1.41M	Buy	485,955 +76,753	+19%	+$264K	0.58%	53
2022 Q4	$1.5M	Buy	409,202 +7,114	+2%	+$21.1K	0.43%	59
2022 Q3	$1.3M	Sell	402,088 -310,921	-44%	-$992K	0.44%	57
2022 Q2	$2.15M	Buy	713,009 +624,730	+708%	+$2.96M	0.66%	39
2022 Q1	$741K	Buy	+88,279	New	+$824K	0.31%	56

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Silverarc Capital Management's CLYM Position: Q2 2026 in Review

Silverarc Capital Management sold out of Climb Bio (CLYM) in Q2 2026, closing a stake of 684,908 shares — an estimated $4.69M sold.

Silverarc Capital Management first reported a position in CLYM in Q1 2022 and held it in 8 quarters. The position peaked at $4.69M in Q1 2026. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

Silverarc Capital Management reported no remaining Climb Bio position as of Q2 2026 after selling out during the quarter.
Silverarc Capital Management sold 684,908 Climb Bio shares in Q2 2026, an estimated $4.69M.
Silverarc Capital Management first reported a position in Climb Bio in Q1 2022 and held it in 8 quarters.
Silverarc Capital Management's Climb Bio position peaked at $4.69M in Q1 2026.
109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.